# Safety Study of Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein Asfotase Alfa in Adults With Hypophosphatasia (HPP)

> **NCT00739505** · PHASE1 · COMPLETED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 6 (actual)

## Conditions studied

- Hypophosphatasia (HPP)

## Interventions

- **BIOLOGICAL:** Asfotase Alfa
- **BIOLOGICAL:** Asfotase Alfa

## Key facts

- **NCT ID:** NCT00739505
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2009-01
- **Final completion:** 2009-02
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2019-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00739505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00739505, "Safety Study of Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein Asfotase Alfa in Adults With Hypophosphatasia (HPP)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00739505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*